The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of FM in the individual.

The present invention relates to a biomarker composition for predicting the therapeutic effect of mesenchymal stem cells on renal fibrosis.

The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.

The present invention relates to a method for diagnosing obesity and liver diseases and method for screening a therapeutic agent for liver diseases using changes in the expression of TM4SF5 protein. In particular, the present invention may be usefully used for measuring changes in the expression of TM4SF5 protein in order to diagnose obesity and liver diseases or screen candidate preventive or therapeutic agents for obesity and liver diseases, by confirming that: in a transgenic mouse having over-expressed TM4SF5 protein, characteristics of fatty liver and hepatitis appear as a metabolic disorder occurs, an increase occurs in the expression of at least one mRNA or protein.

Provided herein is a method for measuring the levels of chronic inflammaging (SCI) of a subject. In some embodiments, the method may comprise measuring the amount of two or more of the proteins CXCL9, TRAIL, IFNG, EOTAXIN and GROA in a sample (e.g., blood serum) from the subject calculating a score based on the weighted amounts of each of those proteins.

Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

The present invention relates to a method of diagnosing over active bladder disorder (OAB), the method comprising: measuring the concentrations of adenosine triphosphate (ATP), acetylcholine (ACh), nitrite, monocyte chemoattractant protein 1 (MCP-1) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP/Cr to 0.000001 mole/mgxdl.sup.1; ACh/Cr to 0.1 mole/mgxdl.sup.1; Nitrite to 200 nM/mgxdl.sup.1; MCP-1/Cr to 100 pgxml.sup.1/mgxdl.sup.1; IL-5/Cr 100 pgxml-mgxdl.sup.1; applying the normalised and range standardised concentrations to the following formula: Logit (p)=1.7381.4044.9852.914subject's age+3315.9595435.254[ATP]/[Cr]+(25204.19420268.337)[ACh]/[Cr]+26.79932.967[nitrite]/[Cr]+6.75525.132 [MCP-1]/[Cr]+(61.838148.740) [IL-5]/[Cr] and calculating Logit; wherein a Logit value above a predetermined threshold indicates that the subject has OAB. Methods for monitoring the progression of OAB using the method, kits for use in the method and computer systems and programs configured to execute the method are also provided.

Method and systems are described comprising receiving a plurality of human subject biomarker concentration values associated with a human subject, wherein the plurality of human subject biomarkers is associated with a condition, determining, based on the plurality of human subject biomarker concentration values, a human subject test statistic, comparing the human subject test statistic to a test statistic threshold, wherein the test statistic threshold is derived based on non-human primate (NHP) subject data, and, determining, based on the human subject test statistic exceeding the test statistic threshold, that the human subject has the condition.

The present disclosure is directed to novel biomarkers useful for staging EHV-1 infections and immunity status of horses. This disclosure is further directed to methods of determining EHV-1 infection stage and immunity status of horses using the novel biomarkers.

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.